|
|
|
CUSIP: G637AM102
Page: 5 of 9
|
|
|
This Amendment No. 3 to Schedule 13D (this Amendment No. 3) relates to
the Common Shares, par value $0.000017727 per share (Common Shares), issued by Myovant Sciences Ltd. (the Issuer), and amends the Schedule 13D filed on January 3, 2020 (the Initial Filing), as amended by
Amendment No. 1 filed on March 18, 2020 and Amendment No. 2 filed on March 26, 2020 (together with the Initial Filing, the Original Schedule 13D and, together with this Amendment No. 3, the
Statement). Capitalized terms used and not defined in this Amendment No. 3 have the meanings set forth in the Original Schedule 13D.
This Amendment No. 3 is being filed by Sumitomo Chemical Co., Ltd., a Japanese corporation (Sumitomo Chemical), Sumitomo
Dainippon Pharma Co., Ltd., a Japanese corporation (Sumitomo Dainippon), and Sumitovant Biopharma Ltd. (formerly known as Vant Alliance Ltd.), a Bermuda exempted company limited by shares (Sumitovant) (collectively, the
Reporting Persons).
This Amendment No. 3 is being filed to amend Item 3 and Item 5 of the Original Schedule 13D as
follows:
Item 3.
|
Source and Amount of Funds or Other Consideration
|
Item 3 of the Original Schedule 13D is hereby supplementally amended as follows:
On March 26, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.9401 per share
for an aggregate purchase price of $555,807, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On March 27, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.975 per share for
an aggregate purchase price of $558,250, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On March 30, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.6538 per share
for an aggregate purchase price of $535,766, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On March 31, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.9712 per share
for an aggregate purchase price of $557,984, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On April 1, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.4614 per share for
an aggregate purchase price of $522,298, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On April 2, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.7298 per share for
an aggregate purchase price of $541,086, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On April 3, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $7.9275 per share for
an aggregate purchase price of $554,925, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.
On April 6, 2020, Sumitovant purchased 70,000 Common Shares of the Issuer in the open market at an average price of $8.436 per share for
an aggregate purchase price of $590,520, all of which was funded through a contribution of working capital from Sumitomo Dainippon to Sumitovant.